CCL2 and lung cancer: In fact, treatment with AT-LXA4, or AT-RvDs strongly reduces tumor growth in a Lewis lung carcinoma cell (LLC; KRASG12C mutated) -derived lung cancer mouse model, by negatively regulating the secretion of pro-inflammatory cytokines including macrophage migration inhibitory factor (MIF), plasminogen activator inhibitor-1 (PAI-1), and C-C motif chemokine ligand 2 (CCL2) and stimulating macrophage phagocytosis of tumor cell debris [111].